Clinical application of CpG-, non-CpG-, and antisense oligodeoxynucleotides as immunomodulators
about
Nucleotide composition of the Zika virus RNA genome and its codon usageVirus-host coevolution: common patterns of nucleotide motif usage in Flaviviridae and their hostsPhosphorylated self-peptides alter human leukocyte antigen class I-restricted antigen presentation and generate tumor-specific epitopesRole of infections in the induction and development of asthma: genetic and inflammatory driversPandemic influenza A virus codon usage revisited: biases, adaptation and implications for vaccine strain developmentRNA editing by the host ADAR system affects the molecular evolution of the Zika virus.The genomic signature of human rhinoviruses A, B and C.Systematic CpT (ApG) depletion and CpG excess are unique genomic signatures of large DNA viruses infecting invertebrates.Toll-like receptor polymorphisms in allogeneic hematopoietic cell transplantation.Genome-wide analysis of codon usage and influencing factors in chikungunya viruses.Genomic analysis of codon usage shows influence of mutation pressure, natural selection, and host features on Marburg virus evolution.Revelation of Influencing Factors in Overall Codon Usage Bias of Equine Influenza VirusesProgress in therapeutic antisense applications for neuromuscular disorders.CpG and UpA dinucleotides in both coding and non-coding regions of echovirus 7 inhibit replication initiation post-entry.Oligonucleotides suppress PKB/Akt and act as superinductors of apoptosis in human keratinocytes.Genetic and evolutionary analysis of emerging H3N2 canine influenza virus.Insights into the genetic and host adaptability of emerging porcine circovirus 3Comprehensive Analysis of Codon Usage on Rabies Virus and Other Lyssaviruses
P2860
Q24497650-7401c03f-4571-2c4b-9723-a5b708735f67Q24498559-1B1815DE-E41C-4D5F-B295-6FDC3BC803C8Q27653670-4EB0E61F-650D-46B5-82E5-CA39C25E2FB8Q28389983-AB6A816C-38AB-4B8C-81EA-A60B97B0DD11Q30423323-AEA43935-4929-4297-9E4A-C37180EAC72BQ33817213-72C3D49A-7381-41B9-B288-3497F771EC67Q34427165-8EC72E89-A81F-4116-A7DA-88E22CECEAD7Q34450614-24BC8711-68F2-4B47-859E-C2D63C24EA7DQ34979770-5D3D8271-E989-42EB-88C9-ABD9D469FC31Q35111153-69392B26-30ED-446A-A81D-8B10D4912B90Q35755118-3BC98C8D-0543-4B29-9D9B-EAE0EF20109FQ36000724-CA483FBB-4284-434E-800D-E4D9E4DE61FFQ37609948-DC9529B9-7803-43D2-A2C3-9BE37BF61E1EQ41928238-618DC910-4FF7-436D-9A7A-3EE15EFE7E9CQ42124172-8E7B2BF8-E10D-4F11-9274-B4B6CE517A54Q52565499-6085EBD2-5186-4384-BB10-B82BB5A2C9BDQ58703500-9A541A6A-2EF1-4DC4-A8A9-02BF5F56645DQ58780070-C5194D4F-4D7C-453D-8035-AAE6EE301817
P2860
Clinical application of CpG-, non-CpG-, and antisense oligodeoxynucleotides as immunomodulators
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Clinical application of CpG-, ...... ucleotides as immunomodulators
@ast
Clinical application of CpG-, ...... ucleotides as immunomodulators
@en
Clinical application of CpG-, ...... ucleotides as immunomodulators
@en-gb
Clinical application of CpG-, ...... ucleotides as immunomodulators
@nl
type
label
Clinical application of CpG-, ...... ucleotides as immunomodulators
@ast
Clinical application of CpG-, ...... ucleotides as immunomodulators
@en
Clinical application of CpG-, ...... ucleotides as immunomodulators
@en-gb
Clinical application of CpG-, ...... ucleotides as immunomodulators
@nl
prefLabel
Clinical application of CpG-, ...... ucleotides as immunomodulators
@ast
Clinical application of CpG-, ...... ucleotides as immunomodulators
@en
Clinical application of CpG-, ...... ucleotides as immunomodulators
@en-gb
Clinical application of CpG-, ...... ucleotides as immunomodulators
@nl
P3181
P1476
Clinical application of CpG-, ...... ucleotides as immunomodulators
@en
P2093
Annette Dorn
Stefan Kippenberger
P3181
P407
P577
2008-02-01T00:00:00Z